- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07228247
Фаза Ⅰ/Ⅱa исследования HMPL-A251 у пациентов с распространёнными или метастатическими HER2-экспрессирующими солидными опухолями
Фаза Ⅰ/Ⅱa исследования по оценке безопасности, переносимости, фармакокинетики, иммуногенности и предварительной эффективности HMPL-A251 у пациентов с распространёнными или метастатическими HER2-экспрессирующими солидными опухолями
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
- To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A251 in participants with previously treated HER2+ solid tumors
- To characterize the safety and preliminary efficacy of HMPL-A251 at RDEs to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected HER2-expressing solid tumors
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
-
Beijing, Китай
- Рекрутинг
- Peking University First Hospital
-
Контакт:
- Shikai Wu
- Номер телефона: +86 18910715326
- Электронная почта: skywu4329@sina.com
-
Контакт:
- Yu Fan
-
Changsha, Китай
- Рекрутинг
- Hunan Cancer Hospital
-
Контакт:
- Quchang Oyang
- Номер телефона: 0731-89762161
- Электронная почта: Oyqc1969@126.com
-
Guangzhou, Китай
- Рекрутинг
- Sun Yat-sen University Cancer Center
-
Контакт:
- Shusen Wang
- Номер телефона: 020-87342693
- Электронная почта: Wangshus@susucc.org.cn
-
Hefei, Китай
- Рекрутинг
- The First Affiliated Hospital of Anhui Medical University
-
Контакт:
- Yingying Du
- Номер телефона: 0551-65908511
- Электронная почта: duyy1980@126.com
-
Shanghai, Китай
- Рекрутинг
- Fudan University Shanghai Cancer Center
-
Контакт:
- Jian Zhang
-
Контакт:
- Xiaohua Wu
- Номер телефона: 18121299168
- Электронная почта: wu.xh@fudan.edu.cn
-
Shenyang, Китай
- Рекрутинг
- The First Hospital of China Medical University
-
Контакт:
- Funan Liu
- Номер телефона: 13609877906
- Электронная почта: lfn_clinical@126.com
-
Zhengzhou, Китай
- Рекрутинг
- Henan Cancer Hospital
-
Контакт:
- Min Yan
- Номер телефона: +86 157 1385 7388
- Электронная почта: ym200678@163.com
-
-
-
-
Colorado
-
Denver, Colorado, Соединенные Штаты, 80218
- Рекрутинг
- SCRI HealthONE
-
Контакт:
- Gerald Falchook
- Номер телефона: 940-365-6217
- Электронная почта: bianca.reyes@scri.com
-
-
Florida
-
Plantation, Florida, Соединенные Штаты, 33322
- Рекрутинг
- BRCR Global
-
Контакт:
- Harshad Amin
- Номер телефона: 561-447-0614
- Электронная почта: alejandrop@brcrglobal.com
-
Plantation, Florida, Соединенные Штаты, 33322
- Рекрутинг
- Florida Clinical Trials Group LLC (Plantation)
-
Контакт:
- Harshad Amin
- Номер телефона: 772-297-3057
- Электронная почта: clinops@floridactg.com
-
Tamarac, Florida, Соединенные Штаты, 33321
- Еще не набирают
- Florida Clinical Trials Group LLC (Tamarac)
-
Контакт:
- Chintan Ghandi
-
-
New Jersey
-
East Brunswick, New Jersey, Соединенные Штаты, 08816
- Еще не набирают
- START New Jersey
-
Контакт:
- Bruno Fang
-
-
New York
-
New York, New York, Соединенные Штаты, 10065
- Еще не набирают
- Memorial Sloan Kettering Cancer Center
-
Контакт:
- Vicky Makker
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Рекрутинг
- Cleveland Clinic Taussig Cancer Center
-
Контакт:
- WenWee Ma
- Номер телефона: 216-559-9815
- Электронная почта: keaneyh@ccf.org
-
-
Washington
-
Tacoma, Washington, Соединенные Штаты, 98405
- Еще не набирают
- Northwest Medical Specialties, PLLC
-
Контакт:
- Jorge Chaves
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Histologically confirmed unresectable advanced or metastatic disease.
- Have at least one measurable lesion per RECIST v1.1;
- Life expectancy ≥ 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
- Weight ≥ 35 kg;
Exclusion Criteria:
- An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.
- Use of strong inhibitors or strong inducers of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;
- Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);
- Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be clinically significant;
- Spinal cord compression, leptomeningeal disease, or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;
- Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study drug(s);
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Part A(Phase I)
Dose Escalation |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
|
Экспериментальный: Part B(Phase IIa)
Dose Expansion/Dose Optimization |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Временное ограничение: Approximately 12 months
|
At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251 |
Approximately 12 months
|
|
Recommended doses for expansion (RDE)
Временное ограничение: Approximately 12 months
|
The RDE will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data, such as chronic toxicities, discontinuations, or withdrawals for toxicity that occur beyond the DLT period; PK data collected at the time of evaluation; Preliminary efficacy data. |
Approximately 12 months
|
|
Overview of Treatment-emergent Adverse Events (TEAEs)
Временное ограничение: Approximately 24 months
|
All TEAEs will be graded according to NCI CTCAE v6.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA). |
Approximately 24 months
|
|
Objective Response Rate (ORR)
Временное ограничение: At least 6 weeks post dose of first participant up to approximately 24 months
|
ORR is defined as the proportion of participants with Best objective response (BOR) of confirmed complete response (CR) or partial response (PR), as per investigator's assessment according to RECIST v1.1. |
At least 6 weeks post dose of first participant up to approximately 24 months
|
|
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251
Временное ограничение: Approximately 12 months
|
The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data. |
Approximately 12 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Disease control rate (DCR)
Временное ограничение: Approximately 2 years
|
The proportion of participants with BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting at least 5 weeks. |
Approximately 2 years
|
|
Duration of response (DoR)
Временное ограничение: Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first occurrence of objective tumor response (CR or PR) to the date of first radiographic PD or death due to any cause. |
Approximately 2 years
|
|
Time to response (TTR)
Временное ограничение: Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first dose of study dose to the first occurrence of objective tumor response (CR or PR) |
Approximately 2 years
|
|
Progression-free survival (PFS)
Временное ограничение: Approximately 2 years
|
The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first. |
Approximately 2 years
|
|
Overall survival (OS)
Временное ограничение: Approximately 2 years
|
Every 12 weeks (± 7 days) until death, withdrawal of consent for follow-up, lost to follow-up or end of study, whichever occurs first. |
Approximately 2 years
|
|
Maximum plasma/serum concentration (Cmax)
Временное ограничение: Cycle 1 and Cycle 3 (21-day cycle)
|
Observed maximum plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609; only applies to Cycles 1 and 3. |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Time to maximum plasma/serum concentration (Tmax)
Временное ограничение: Cycle 1 and Cycle 3 (21-day cycle)
|
Time to observed Cmax for HMPL-A251, total anti-HER2 antibody, and HM5041609 |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Area under the plasma/serum concentration-time curve (AUC)
Временное ограничение: Cycle 1 and Cycle 3 (21-day cycle)
|
Derived from the observed plasma/serum concentration-time data for HMPL-A251, total anti-HER2 antibody, and HM5041609 using noncompartmental analysis |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Pre-dose plasma/serum concentration (Cmin)
Временное ограничение: Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
Observed pre-dose plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609. |
Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
|
Immunogenicity of HMPL-A251
Временное ограничение: Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Incidence of anti-drug antibody and neutralizing antibody against HMPL-A251 |
Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- 2025-251-GLOB1
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .